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Background: There is an agreement that the methodological quality of randomized
trials should be assessed in systematic reviews, but there is a debate on how this
should be done. We conducted a construct validation study of the Physiotherapy
Evidence Database (PEDro) scale, which is widely used to assess the quality of tri-
als in physical therapy and rehabilitation.
Methods: We analyzed 345 trials that were included in Cochrane reviews and for
which a PEDro summary score was available. We used one- and two-parameter
logistic item response theory (IRT) models to study the psychometric properties of
the PEDro scale and assessed the items' difficulty and discrimination parameters.
We ran goodness of fit post estimations and examined the IRT unidimensionality
assumption with a multidimensional IRT (MIRT) model.
Results: Out of a maximum of 10, the mean PEDro summary score was 5.46 (SD
= 1.51). The allocation concealment and intention-to-treat scale items contributed
most of the information on the underlying construct (with discriminations of 1.79
and 2.05, respectively) at similar difficulties (0.63 and 0.65, respectively). The
other items provided little additional information and did not distinguish trials of
different quality. There was substantial evidence of departure from the unidimen-
sionality assumption, suggesting that the PEDro items relate to more than one
latent trait.
Conclusions: Our findings question the construct validity of the PEDro scale to
assess the methodological quality of clinical trials. PEDro summary scores should
not be used; rather, the physiotherapy community should consider working with
the individual items of the scale.
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1 | INTRODUCTION
Systematic reviews and meta-analyses of randomized trials
have a pivotal role informing clinical practice and policy
decisions,1 and there is a broad agreement that the methodo-
logical quality of primary studies should be carefully
assessed. However, study quality is a hazy concept that lacks
a commonly agreed definition and a solid theoretical frame-
work: Many of the available tools to assess study quality
lack both theoretical and empirical support.2-4 The quality of
randomized trials was originally defined as “the confidence
that the [study] design, conduct, and analysis has minimized
or avoided bias.”5 In line with this definition, the Cochrane
Collaboration distinguishes between the methodological
quality of a study and the risk of bias: A study of high qual-
ity can still be at high risk of bias.6 For example, in physio-
therapy and other nonpharmaceutical interventions, the
blinding of study participants may be impossible even in
studies that otherwise meet high methodological standards.
The Cochrane risk of bias (RoB) tool exclusively focuses on
the internal validity of trials.6,7 Others extend quality assess-
ment to include elements of external validity and the preci-
sion of estimates or sample size or to items related to the
completeness of the reporting of trials.8
The impact of study quality or risk of bias on the results
of trials has been studied for different scales and checklists
(ie, criterion and/or convergent validity)9-11 but evidence to
support construct validity is sparse. Although the empirical
demonstration of construct validity is strictly not possible,
evidence is needed to establish not only the salience of exis-
ting measures to the study quality construct but also the
extent to which study quality is a coherent concept. More-
over, there is little recognition that, from a test theory view-
point, there are important differences between scales and
checklists.12 Their interchangeable use is problematic, for
example, when checklists are turned into scales simply by
assigning 1 point to every item, and overall scores are com-
puted.13 Scales use several items to assess one underlying
construct (a latent trait) that cannot be directly observed, for
example, “study quality.” The combination of individual
responses into an overall score is meaningful only if all
items relate to the same latent construct (unidimensionality)
and are correlated indicators of this construct (internal con-
sistency), rather than variables causing the construct.12,14
In contrast to scales, checklists may relate to different
constructs, and they may include both indicators of effects
of the underlying construct and indicators of causes of the
construct.14 For example, the Cochrane RoB tool assesses
the blinding or lack of blinding of study participants and per-
sonnel, which may prevent or cause performance bias.6,7
Similarly, it assesses concealment of allocation to treatment,
which may prevent selection bias. Of note, while the latter
can always be implemented in a trial, the former may be
impossible; consequently, the correlation between the two is
often low. These items should therefore not be combined in
a scale and summary score. Another problem of summary
scores relates to the implicit assumption that all scale items
contribute equally to the overall score, whereas in practice,
their importance and correlation with the underlying con-
struct vary and will depend on the type of intervention and
outcome, and context in general.2,15 Cutoffs along the con-
tinuum of summary scores are often used to denote “ade-
quate quality” and to decide on inclusion or exclusion of
studies in systematic reviews and meta-analyses, which may
introduce bias.16,17
In this study, we focus on the Physiotherapy Evidence
Database (PEDro) scale, which is widely used to assess the
methodological quality of clinical trials in the field of physi-
cal therapy and rehabilitation. The development and evalua-
tion of the PEDro scale have been exceptionally
Highlights
What is already known
• There is a debate and variation in practice
between different fields over how to assess qual-
ity and the potential for bias in randomized trials.
What is new
• This is the first comprehensive and independent
construct validation study of a widely used qual-
ity scale, the Physiotherapy Evidence Database
(PEDro) scale using item response theory models
in a large sample of physiotherapy trials. Our
findings show that the PEDro scale to assess the
quality of randomized trials has poor construct
validity, with items capturing more than one
underlying trait.
Potential impact
• The research synthesis community should agree
on a common theoretical framework and
approach to assessing quality and risk of bias in
trials that are both valid and consistent. The use
of summary scores to screen and select random-
ized trials in physical therapy and other fields
should be discouraged. Rather, reviewers should
assess different domains of bias separately, as
recommended by the Cochrane Collaboration.
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meticulous.18,19 However, unsurprisingly, there is debate
about the pitfalls of using summary scores to assess study
quality and risk of bias.17,20 Although modern validation
studies increasingly use item response theory (IRT) to exam-
ine the discrimination of different items included in a scale
and their coverage of the latent (underlying) construct,21,22
no such studies have been performed for the PEDro scale.
We therefore examined the construct validity of the PEDro
scale using IRT models in a large sample of physiotherapy
trials.16
2 | METHODS
2.1 | The PEDro scale
PEDro23 is a web-based repository of currently over 42 000
RCTs of physical therapy that have been systematically
assessed by two independent reviewers using the PEDro
scale.24 Figure 1 details the 11 items included in the PEDro
scale. Eight items relate to the design and conduct of the
trial, and three are concerned with reporting eligibility
criteria (item 1), between-group statistical comparisons (item
10), and measures of variability (item 11). Notably, only two
of the three items on reporting quality contribute points to
the total score: The item on eligibility criteria does not.
Therefore, the summary score ranges between 0 and 10
rather than 11 points, and usually trials are regarded to be of
moderate or high quality if they score six points or more.24
The PEDro scale was developed for clinical trials of physical
therapy. However, it does not contain items that are specific
to this field,17,18 and it has been used in other fields, for
example, in reviews of drug interventions in dementia or
pain.23,25
2.2 | Study sample
Described in detail elsewhere,16 we analyzed 345 physio-
therapy trials that were included in systematic reviews publi-
shed in the Cochrane Database of Systematic Reviews
(CDSR). Briefly, we searched the CDSR from 1 January
2005 to 25 May 2011 for meta-analyses of physical therapy
interventions. Meta-analyses were eligible if they included at
least three trials of physiotherapy as defined by the World
Confederation for Physical Therapy (WCPT) with a continu-
ous outcome.26 A PEDro score was already available in the
online PEDro database for 333 of the 345 trials (94.3%).
Thus, almost all trials of our sample were independently
assessed by two independent PEDro reviewers.19 The 12
remaining RCTs were assessed by two independent asses-
sors, who were trained by an experienced meta-analyst (S.A-
O), with 100% agreement between the two assessors who
scored the 12 RCTs.16
2.3 | Statistical methods
We used Wilcoxon rank-sum tests and Fisher exact tests to
compare the trials of moderate to high quality (PEDro score
≥6) with trials of lower quality for continuous and categori-
cal variables, respectively. We assessed correlation of each
item with the summary PEDro score (including all items)
using Pearson correlation coefficients and the internal con-
sistency based on Cronbach alpha and its standardized ver-
sion, Guttman lambda 6, the averaged between-item
correlation (mean and median), and the signal-to-noise ratio.
To address potential multidimensionality, we used a strati-
fied version of Cronbach alpha and McDonald omega
assuming one, two, or three underlying dimensions.
We computed a series of IRT models to study the psy-
chometric properties of the PEDro scale. In IRT models, the
relationship between the PEDro scale's dichotomous item
responses (no = 0; yes = 1) and the underlying latent trait
(RCT quality) are described by the item characteristic curve
(ICC). For each scale item, the ICC displays the probability
of responding “yes” in relation to the latent trait θ, the study
quality. This probability follows a cumulative logistic distri-
bution and increases as the latent trait increases, ie, the prob-
ability for a “yes” increases with study quality. The latent
trait is on a standard normal scale, ie, 95% of the studies are
expected to have a quality between −1.96 and 1.96. The
ICC is characterized by two parameters, the item difficulty
(or location) and the discrimination. The latter is assumed to
be identical for all items in one-parameter logistic (1PL)
models (which corresponds de facto to the classical Rash
model) but varies across items in two-parameter logistic
(2PL) models. The item difficulty reflects the study quality
that is required to have a 50-50 chance of responding “yes.”
The discrimination is the slope of the ICC and captures how
well an item can distinguish between different levels of the
latent trait around the item difficulty. An item with a large
discrimination (and a steep ICC) is answered differently for
studies of different quality.
We ran standard 1PL, and 2PL IRT models for PEDro
items, and a 2PL multidimensional IRT (MIRT) model with
two-dimensions (2D 2PL). We compared the goodness of fit
of these models using likelihood ratio tests and global fit sta-
tistics including the Akaike information criteria (AIC), the
Bayesian information criteria (BIC), the M2 statistic,27 the
root mean square error of approximation (RMSEA), the stan-
dardized root mean square residual (SRMSR), the Tucker-
Lewis index (TLI), and the comparative fit index (CFI). We
analyzed item fit based on a signed chi-squared statistic and
the RMSEA.28 For the unidimensional models, we also cal-
culated infit and outfit mean square statistics that focus on
the differences near or at the extreme of the θ values, respec-
tively. We also assessed person-fit using the person-fit based
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TABLE 1 Trial characteristics by Physiotherapy Evidence Database (PEDro) scores of below 6 or 6 and above
All Trials PEDro Score <6 PEDro Score ≥6 P Value*
Number of trials 345 188 157
PEDro score 5.00 (4.00-7.00) 5.00 (4.00-5.00) 7.00 (6.00-7.00) <.001
Year of publication 2002 (1998-2004) 2000 (1997-2004) 2003 (1999-2005) <.001
Trial design .25
Parallel 322 (93%) 174 (93%) 148 (94%)
Factorial 15 (4.3%) 7 (3.7%) 8 (5.1%)
Crossover 7 (2.0%) 6 (3.2%) 1 (0.6%)
Cluster 1 (0.29%) 1 (0.53%) 0 (0.0%)
Multicentric study 85 (25%) 30 (16%) 55 (35%) <.001
Hypothesis .41
Superiority 317 (92%) 169 (90%) 148 (94%)
Equivalence 15 (4.3%) 11 (5.9%) 4 (2.5%)
Noninferiority 4 (1.2%) 2 (1.1%) 2 (1.3%)
Unclear/no comparison 9 (2.6%) 6 (3.2%) 3 (1.9%)
Placebo-controlled 28 (8.1%) 9 (4.8%) 19 (12%) .017
Study population .20
Adult 218 (63%) 122 (65%) 96 (61%)
Geriatric 116 (34%) 57 (30%) 59 (38%)
Pediatric 5 (1.4%) 4 (2.1%) 1 (0.6%)
Unclear 6 (1.7%) 5 (2.7%) 1 (0.6%)
Interventions .031
Exercise 266 (77%) 154 (82%) 112 (71%)
Education 9 (2.6%) 5 (2.7%) 4 (2.5%)
Manual therapy 13 (3.8%) 4 (2.1%) 9 (5.7%)
Acupuncture 8 (2.3%) 1 (0.53%) 7 (4.5%)
Other 49 (14%) 24 (13%) 25 (16%)
Outcome source .036
Clinician assessment 128 (37%) 82 (44%) 46 (29%)
Self-reported 180 (52%) 86 (46%) 94 (60%)
Laboratory data 15 (4.3%) 9 (4.8%) 6 (3.8%)
Administrative data 22 (6.4%) 11 (5.9%) 11 (7.0%)
Sample size
Randomized 72.0 (41.0-148) 59.0 (32.0-109) 104 (60.0-191) <.001
Analyzeda 63.0 (37.0-128) 49.0 (30.0-95.0) 93.0 (54.0-170) <.001
Fundingb
Industry 36 (10%) 17 (9.0%) 19 (12%) .86
Government 183 (53%) 79 (42%) 104 (66%) .002
Academic 41 (12%) 23 (12%) 18 (11%) .50
Foundation 96 (28%) 46 (24%) 50 (32%) .70
No funding 18 (5.2%) 12 (6.4%) 6 (3.8%) .22
Not declared 69 (20%) 50 (27%) 19 (12%) .001
Note. Numbers (%) or medians (interquartile range) are shown.
aUnknown for 10 trials with a PEDro score <6 and 1 trial with a PEDro score ≥6.
bDoes not add up to 100% as multiple entries are possible.
*P values obtained from Wilcoxon rank-sum and Fisher exact tests for continuous and categorical variables, respectively.
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on the Zh value29 (for more details, see Tables S8, S9, S10,
and S11).
We calculated the ICC and the item information func-
tions (IIF) of all items, where “information” refers to the pre-
cision of a scale in measuring the latent trait, and each item
has greatest precision around its estimated difficulty parame-
ter. Technically, the information is the negative of the expec-
tation of the second derivative of the log-likelihood with
respect to the latent trait θ. We used the item information
functions to depict the coverage and precision of the items
with respect to the spectrum of the clinical trials' quality. We
included item 1 of the PEDro scale (eligibility criteria) in all
IRT models.
IRT models are based on two key assumptions: that the
scale items draw on only one underlying latent trait (unidi-
mensional latent space) and that the item responses are inde-
pendent and conditional only to the level of the underlying
trait (local or conditional independence). We formally tested
the former assumption comparing the multidimensional 2D
2PL model with the unidimensional models (Appendix S1,
section 1.3). We assessed local independence for all IRT
models using the local dependence statistic between each
pair of items (a signed chi-squared value) and its standard-
ized version (Cramer V) (Appendix S1, section 1.5).30
All analyses were done in Stata version 14 (StataCorp,
College Station, Texas) and R (R Foundation for Statistical
Computing, Vienna, Austria), using Stata routines irt 1PL
and irt 2PL, and the R MIRT packages (2D 2PL model).
3 | RESULTS
3.1 | Characteristics of sample of 345
physiotherapy trials
As shown in Figure 1, the counts of yes/no responses varied
markedly across the 11 items of the PEDro scale. For exam-
ple, blinding of subjects (item 5) and of therapists (item 6)
were virtually never implemented, while items related to
random allocation of participants to groups (item 2),
reporting of between-group comparisons (item 10) or
reporting of both point estimates and measures of variability
(item 11) were almost always met. Consequently, only 10
trials (3%) had either a very low (<3) or very high score
(>8), and most quality scores ranged between 4 and 7 with
a maximum of 10 (median = 5, interquartile range = 4-7,
mean = 5.46, SD = 1.51). Of note, item 1 (eligibility
criteria), which was not used in the calculations of the over-
all score, showed results similar to item 4 (baseline compa-
rability). Trials with PEDro scores below six points differed
from those with higher PEDro scores (Table 1). The latter
were published more recently, and were more likely to be
multicentric trials and placebo controlled. Trials with higher
PEDro scores also had larger sample sizes and were more
likely to report the source of funding and to be funded by
government grants.
3.2 | Internal consistency
Some of the items correlated only weakly with the summary
PEDro score (Table S20), in particular, item 1 (eligibility,
Pearson correlation coefficient (ρ) = .29; 95% confidence
interval [CI], 0.19-0.38), item 2 (random allocation, ρ = .2;
95% CI, 0.10-0.30), item 5 (blinding of subjects, ρ = .29;
95% CI, 0.19-0.38), and item 10 (between-group compari-
sons, ρ = .19; 95% CI, 0.09-0.29). Consequently, internal
consistency of the PEDro items was low (Cronbach alpha =
.56; 95% CI, 0.50-0.63; stratified Cronbach α with two
dimensions = .59; McDonald omega with two dimensions =
.58) with a mean correlation of 0.11 (Table S21).
3.3 | Model fit
The two-parameter logistic (2PL) and the two-dimensional
two-parameter logistic (2D 2PL) models showed a reason-
able global fit (eg, M2 of 42.8, P = .17, and 18.6, P = .85;
Table S6), whereas the one-parameter (1PL) model did not
(eg, M2 of 74.2, P = .003). The 2PL model fitted better than
the 1PL model (P = .001 from likelihood ratio test), indicat-
ing that the assumption of a common discrimination does
not hold. All models struggled to fit items 2 (random alloca-
tion) and 5 (blinding of subjects), which showed a very high
and a very low proportion of positive responses,
respectively.
3.4 | Results from two-parameter logistic
model
Table 2 shows the difficulty and discrimination coefficients
from the 2PL model, Figure 2 the item characteristics curves
(ICC), and Figure 3 the item information functions (IIF).
Results from the 1PL and the 2D 2PL models are presented
in Tables S1 and S3, and Figures S1 and S2, respectively. In
the 2PL model, the difficulty coefficient of items 2 (random
allocation), 10 (between-group comparisons), 11 (variability
measures), and 5 (blinding of subjects) were either highly
negative (below −2.9, ie, “too easy”) or highly positive
(above 3.6, ie, “too hard”) and thus contributed little infor-
mation on the quality of trials in the normal range. Interest-
ingly, these items all loaded on the same latent trait in the
2D 2PL model (Table S5), indicating that they relate to
another latent trait.
The slopes of the ICCs for items 8 (complete follow-up)
and 10 (between group comparison) were both flat, indicat-
ing that these items cannot distinguish well between trials of
different quality level. For item 8, that was also true for the
2D 2PL model, where the item failed to discriminate
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between the two latent traits. Most of the information was
provided by item 3 (allocation concealment) and item 9
(intention-to-treat analysis) with the highest discriminations
(1.79 and 2.05, respectively); however, these two items had
almost identical difficulty (0.63 and 0.65, respectively) and
thus conveyed similar information regarding the underlying
construct (ie, quality of trials). These items mainly loaded on
the second latent trait in the 2D 2PL model.
3.5 | Dimensionality and local independence
The 2D 2PL fitted better than the unidimensional 2PL
model, indicating that the PEDro scale may rely on more
than one underlying latent trait or dimension (Tables S6 and
S7; all fit indices were improved and P = .004 in a likeli-
hood ratio test). In the 2D 2PL model, items 1 (eligibility
criteria, which is not computed for the overall score), 3 (allo-
cation concealment), and 9 (intention-to-treat) loaded on one
dimension and items 2 (random allocation), 5 (blinding of
subjects), 10 (between group comparison), and 11 (point and
variability measure) on the other (Table S5). Items 4 (bal-
anced at baseline) and 7 (blinding of assessors) showed
cross-loading on both dimensions, whereas item 8 (complete
follow-up) struggled to load on any of them. Finally, we
found evidence for local dependence for six combinations of
items in the 1PL model and for one only in the 2PL model
(items 3 and 7) and for none in the 2D 2PL model (Tables
S12 to S14).
FIGURE 1 Items of the
Physiotherapy Evidence Database (PEDro)
scale and their distribution in the
validation dataset of 345 trials. Item
1 (eligibility criteria) does not contribute to
the total score
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4 | DISCUSSION
We conducted an independent construct validation study
based on IRT models to assess the psychometric properties
of a scale that is widely used to measure the quality of
clinical trials in physical therapy and rehabilitation and to
determine inclusion or exclusion of trials in systematic
reviews and meta-analyses. We validated the instrument in a
large “real-world” sample of trials that were both included in
Cochrane reviews and assessed in the PEDro database. We
TABLE 2 Items of the Physiotherapy Evidence Database (PEDro) scale with the coefficients for difficulty and discrimination from the item
response theory two-parameter logistic model
Item No. Description Label
Difficulty
(95% CI)
Discrimination
(95% CI)
1a Eligibility criteria were specified Eligibility −1.50 (−1.98 to −1.03) 1.43 (0.76 to 2.09)
2 Subjects were randomly allocated to groups Random allocation −4.02 (−7.25 to −0.80) 1.16 (−0.05 to 2.36)
3 Allocation was concealed Allocation concealment 0.66 (0.43 to 0.89) 1.79 (1.08 to 2.51)
4 The groups were similar at baseline regarding
the most important prognostic indicators
Baseline comparability −1.47 (−1.93 to −1.01) 1.46 (0.78 to 2.13)
5 There was blinding of all subjects Blinding of subjects 3.69 (1.34 to 6.04) 1.03 (0.20 to 1.86)
6 There was blinding of all therapists who
administered the therapy
Blinding of therapists Not estimatableb Not estimatableb
7 There was blinding of all assessors who measured
at least one key outcome
Blinding of assessors 0.25 (−0.02 to 0.51) 0.99 (0.59 to 1.39)
8 Measures of at least one key outcome were
obtained from more than 85% of the
subjects initially allocated to groups
Complete follow-up −1.48 (−2.53 to −0.43) 0.45 (0.15 to 0.76)
9 All subjects for whom outcome measures were
available received the treatment or control
condition as allocated or, where this was not
the case, data for at least one key outcome
was analyzed by “intention to treat”
Intention-to-treat 0.63 (0.42 to 0.85) 2.05 (1.15 to 2.96)
10 The results of between-group statistical comparisons
are reported for at least one key outcome
Between-group
comparisons
−9.37 (−28.16 to 9.42) 0.36 (−0.39 to 1.11)
11 The study provides both point measures and
measures of variability for at least one key
outcome
Measures of variability −2.94 (−4.47 to −1.40) 0.93 (0.33 to 1.53)
aItem 1 (eligibility criteria) does not contribute to total score.
bThe parameters were not estimatable for item 6 because blinding of therapist was never implemented.
FIGURE 2 Item characteristic curves from
the two-parameter logistic model [Colour figure
can be viewed at wileyonlinelibrary.com]
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found that the scale items used to compute the PEDro study
quality score captured more than one underlying trait. Some
items seemed to convey similar, limited, or no information
about the methodological quality of the clinical trials. Our
results corroborate earlier criticisms of quality scales in gen-
eral2,15,31 and of the PEDro scale in particular.16,17
Strengths of the present study include the use of IRT
models, which go beyond previously used Rasch models,32
and the independence of our group, which is not associated
with the PEDro database and scale. Several limitations are
worth noting. Because we used a sample of 345 highly rele-
vant trials that were included in Cochrane reviews, their
average study quality was higher than the average reported
in the PEDro online archive. Although the main features of
our sample did not differ from those of trials included in the
PEDro repository, we acknowledge that our validation study
might produce different results in different groups of trials.
In other words, it is unclear whether the lack of construct
validity extends to trials of low quality. Difficulty and dis-
crimination estimates were outside the typical range for
some of the items and showed large uncertainty, which was
attributable to a low frequency of negative or positive
responses. These point estimates therefore have to be inter-
preted with care. We did not include multidimensional IRT
models with more than two dimensions as they might be sus-
ceptible to overfitting for an 11-item scale. The likely num-
ber of underlying dimensions remains unclear. However, an
in-depth analysis of the structure of underlying latent traits
was beyond the scope of this study. Based on our results
from the 2D 2PL model, it seems likely that items 1, 3, and
9 and items 2, 5, 10, and 11 relate to distinct latent traits,
with items 4 and 7 loading on both of those traits.
Evidence on the construct validity of the PEDro scale is
scarce and comparisons with previous studies not straightfor-
ward. Previous studies used simple linear regressions11,33 or
Rasch analysis32 to assess construct validity. However, linear
regressions will only provide information about criterion
validity, not on construct validity. Although the Rasch model
corresponds to a 1PL IRT model, we found that the 1PL did
not fit our data well. Our main results are based on the 2PL
model where difficulty and discrimination parameters are
allowed to vary across items. Further, in contrast to de Morton
et al,32 there were important departures from the unidimen-
sionality assumption. Replications in other samples are
warranted, but these departures are unlikely to depend on the
RCTs included in our study.
We found evidence of violations of local independence
(the second assumption of IRT models), which were likely
due to redundancy of items. Although item reduction was
done during the development phase of the PEDro scale,
future studies should consider whether two or more items in
the current version are linked and whether there is any “car-
ryover” from one item to the next, both of which cause vio-
lations of the local independence assumption.
The PEDro database, which includes many thousands of
carefully assessed trials, is an extremely valuable resource
for the evaluation of interventions in physical therapy and
rehabilitation.34 In many respects, the development of the
PEDro quality scale was exceptionally thorough.8 However,
the PEDro scale intentionally includes two sets of items that
capture internal validity (ie, “believability,” items 2 to 9)
and reporting quality (“interpretability,” items 10 and 11),
respectively. While item 1 does not contribute to the score,
items that do not relate to the same underlying construct by
design do contribute. In addition, the operationalization of
some of the items seems problematic. For example, item 4 is
a composite item, which enquires about both similarity
between groups and prognostic indicators, and judgement
for item 8 is based on the (implicit) assumption that less than
15% overall attrition is unproblematic, which is questionable
and unsubstantiated. Further studies support the reliability18
and convergent validity of the PEDro scale.33 Nevertheless,
our results question the construct validity of the PEDro scale
in its current form and, therefore, support recommendations
FIGURE 3 Item information functions (IIF)
from the two-parameter logistic model for all
PEDro items. Items 3 and 9 contributed the most
information but at the same trial quality. The
coverage for qualities larger than 2 was poor
[Colour figure can be viewed at wileyonlinelibrary.
com]
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of Cochrane and many methodologists that the use of sum-
mary scores should be discouraged.2,6,15,31,35
In conclusion, our study provides robust empirical evi-
dence to suggest that the PEDro scale as currently con-
structed and used is not psychometrically sound and should
not be used to assess study quality. The PEDro instrument
might be improved by removing redundant items, by revis-
ing others, and by clarifying the different underlying con-
cepts of risk of bias, study quality, and completeness of
reporting. The PEDro database and physical therapy com-
munity should now consider working with the assessments
of the individual items of the scale, revising some of these
items taking into account recent developments,7,35 and
refrain from computing and using summary scores. Finally,
our results are relevant to the evidence synthesis community
beyond PEDro, because they clearly demonstrate that we
should agree urgently on an approach to assessing quality
and RoB in trials that is both valid and consistent.
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